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Abstract
Background: Avian influenza H5N1 virus is highly pathogenic partially because its H5 hemagglutinin contains a
polybasic cleavage site that can be processed by proteases in multiple organs.
Methods: Monoclonal antibodies (mAb) specific to the synthetic peptide of hemagglutinin polybasic cleavage site
of H5N1 virus were raised and tested for their neutralizing potential.
Results: Purified mAb showed suppression of H5N1 pseudovirus infection on Madin-Darby Canine Kidney (MDCK)
cells but the efficacy was less than 50%. Since those mAb are specific to the intact uncut polybasic cleavage site of
hemagglutinin, their efficacy depends on the extent of hemagglutinin cleavage on the viral surface.
Conclusions: Proteolytic analysis suggests the low efficacy associated with those mAb may be due to proteolytic
cleavage already present on the majority of hemagglutinin prior to the infection of virus.
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Background
Avian H5N1 highly pathogenic influenza virus was first
isolated from sick geese in China during 1996 and later
transmitted to human in Hon Kong during 1997 [1].
This H5N1 virus was spread throughout Asia and over
as far as Europe or Africa by migratory birds in 2005
[1], which prompted a fear of global pandemic. Avian
H5N1 Influenza virus has two major antigenic surface
proteins, hemagglutinin (HA) and neuraminidase (NA),
and a RNA genome which accumulates mutations
rapidly over its life cycles [2]. The rapid accumulation of
genomic mutations results in frequent alterations on the
surface epitopes that is known as antigenic drift [3]. The
function of HA is to recognize host sialic acid residue as
an entry receptor [4,5], and to fuse viral envelope with
vesicle’s membrane [5,6] after the linker peptide
between subdomain HA1 and HA2 of HA is cleaved by
host trypsin-like proteases. Virulent H5 and H7 hemag-
glutinins [7] have a polybasic cleavage site that is
exposed and cleavable by furin or other proprotein
convertases [8,9] which enables the virus to infect multi-
ple organs and leads to multisystem failure [7]. A sec-
ond factor correlating to the high pathogenicity of
H5N1 influenza virus is the PB2 subunit in polymerase
complex [10,11]. The adaptation of viral polymerase
complex to replicate in mammalian host cell is an
important factor for the high pathogenicity associated
with influenza virus [12,13]. The combination of polyba-
sic H5 HA and humanized PB2 in the avian H5N1 virus
m a k e si th i g h l yp a t h o g e n i ca n dap a n d e m i cp o s s i b l e
with high mortality and morbidity similar to that of
1918, if this H5N1 virus ever adapts to human cell’s
entry receptor with an a-2,6 sialo-galactose linkage [14].
There are many antiinfluenza measures available. For
example, vaccination is a good defense against highly
pathogenic influenza like the avian H5N1 virus [15,16],
but antigenic drift associated with influenza virus enables
its evasion from host immunity and necessitates vaccina-
tion every year/season. Amantadine and Rimantadine tar-
get viral M2 channel protein during the viral endocytosis
[17], but amantadine suffers from the prevalence of drug
resistant viruses [18] and both compounds possess side
effect on host central nervous system [19]. Oseltamivir
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any medium, provided the original work is properly cited.and Zanamivir target viral neuraminidase activity during
viral budding [17], but avian H5N1 as well as seasonal
influenza viruses resistant to Oseltamivir have been
reported [20-22]. Ribavirin targets viral polymerase activ-
ity, but its side effect is a major concern [23]; therefore, a
new approach of suppressing influenza virus infection is
highly desirable.
An antibody targeting the conserved epitopes on viral
surface may be able to circumvent the antigenic drift
and thus avoid the hit-and-miss situation associated
with influenza vaccines. For example, the ectodomain of
M2 channel protein is highly conserved among most
strains of influenza A viruses and has been targeted as a
broad spectrum epitope, but the antibody will only work
on influenza A viruses and as the mutations accumulate
at the ectodomain of M2 protein, they count against the
efficacy of such antibody [24]. The HA2 domain of
hemagglutinin is also conserved but is much more
hydrophobic when compared to HA1 domain [25], pos-
sibly due to its role at facilitating membrane fusion dur-
ing viral infection [5,6]. Few antibodies specific to this
hydrophobic region have been reported so far [25] but
antibodies of this type enjoy a broad spectrum reactivity
[26-29]. For example, a pan influenza A antibody speci-
fic to an HA2 epitope was able to recognize all 16 sub-
types of HA and neutralize group1 H1 and group 2 H3
[27].
The polybasic cleavage site on hemagglutinin is highly
conserved among those highly pathogenic H5N1 viruses
and its polybasic residue constituent should make this
peptide fairly antigenic but discernable from other hydro-
phobic peptides and, therefore, this polybasic peptide is
an interesting candidate as a broad spectrum epitope.
Because the proteolytic cleavage of HA is a necessary
step for an influenza virus to become infectious, we
hypothesize that monoclonal antibody (mAb) specific to
the polybasic cleavage site on hemagglutinin may be able




The polybasic cleavage site on hemagglutinin is highly
conserved among H5N1 avian influenza viruses [7,30,31],
but to ensure a successful raise of hybridoma cell lines,
two different constructs were derived from the polybasic
cleavage site, RERRRKKR, when raising mAb. One con-
struct, RERRRKKR↓GLFGAIAGFI-ovalbumin (OVA, ↓
depicts HA cleavage site) gave rise to 3 monoclonal
hybridomas, clone 3C4, 4H2, and 6B8; whereas
RERRRKKR↓GLFGAIAC-keyhole limpet hemocyanin
(KLH) gave rise to clone A, B, C, and D. Each mouse was
immunized with approximately 50 μg antigen which was
emulsified in 150 μLo fF r e u n d ’s complete adjuvant and
boosted with the same dose of antigen but emulsified in
incomplete adjuvant 14 days later.
Purification of mAb
Those 7 hybridomas were cultured to raise ascitic fluid in
nude mice and the mAb was purified by protein A resin
(Pierce/Thermo Scientific, Rockford, IL). Briefly, monoclo-
nal antibodies in the ascitic fluid was precipitated by 50%
saturation of ammonium sulfate and redissolved in a mini-
mal volume of phosphate buffered saline (PBS) before an
overnight dialysis. Dialysed ascitic fluid was loaded onto a
protein A column that had been equilibrated with 20 mM
sodium phosphate pH7 buffer. The monoclonal antibody
was eluted with 100 mM acetic acid pH2.8 and neutralized
by 1 M Tris/HCl pH9. The immunoglobulin in elution
was concentrated with Centricon (Millipore, Billerica,
MA) and the contents were determined by Bradford pro-
tein assay (BioRad, Hercules, CA).
Pepsin treatment of mAb
One mg of pepsin (Sigma P6887) was predissolved in 200
μL of 0.1 M glycine acetate (pH 2.6). Twenty μLo fm A b
was added with an equal volume of pepsin and digested at
37°C for 40 min before 1 μLo f1MT r i s( p H9 )w a sa d d e d
to alleviate the protein precipitation due to acidity. The
mixture was further incubated for 30 min before 4 μLo f
1 M Tris (pH9) was added to stop the reaction. An aliquot
of 225 μL D-MEM was added to the antibody/pepsin mix-
ture and 50 μL of the mixture was used for pseudovirus
neutralization assay.
Epitope peptide analysis
Three synthetic peptides were used to evaluate the epitope
binding property of those 7 purified monoclonal antibo-
dies. The full length 18 meric peptide, RERRRKKRGLF
GAIAGFI, the N-half 8 meric peptide, RERRRKKR, and
the C-half 10 meric peptide, GLFGAIAGFI, were synthe-
sized at the Genomic Research Center of Academia Sinica.
All 3 peptides were dissolved in DMSO at 2 mg/mL con-
centration. An aliquot of 5 μL( 1 0μg) was spotted on a
1 cm square of PVDF membrane (Perkin-Elmer, Waltham,
MA). Four ten-fold serial dilutions were also spotted on
the membrane similarly. The PVDF membranes were
allowed for air dry and subject to immunoblotting after
the membrane being rewetted by methanol/PBS. Blocking
of the PVDF membrane was carried out with 2% non-fat
milk dissolved in PBS. The purified monoclonal antibodies
were diluted 500 fold in 2% non-fat milk and allowed for 1
hr incubation with the membrane. Horseradish peroxidase
(HRP) conjugated anti-mouse 2
nd antibody was used to
probe the membrane at 1:5000 dilution for 1 hr. The
immunoreactive spots were developed with a chemilumi-
nescent substrate (Invitrogen, Carlsbad, CA) and scanned
with a typhoon scanner (Amersham).
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T oa v o i du s i n gt h o s eh i g h l yp a t h o g e n i cH 5 N 1v i r u s e s ,
pseudoviruses comprised of HA5 and NA1 antigens,
Pol and Gag of HIV and a firefly luciferase reporter
gene [32] were kindly provided by Min-Wei Chen with
permission from Dr. David Ho. Three different H5N1
strains of pseudoviruses were used in the neutralization
assay: 1) Vietnam 1194 H5N1 pseudovirus that has the
consensus sequence, RERRRKKRGLFGAIAGFIEGG; 2)
Turkey 2005 H5N1 pseudovirus that has an R339G
mutation in its sequence, GERRRKKRGLFGAIAG-
FIEGG, mutation underlined; 3) Anhui 2005 H5N1
pseudovirus, RERRR_KRGLFGAIAGFIEGG, which has
a deletion of K344 or K345 at the polybasic site. The
peptide sequence of antigens and viral cleavage sites
were listed in Table 1 for comparison. A vesicular sto-
matitis pseudo-virus (VSV) was employed as a negative
control. All pseudoviruses were reconstituted in 293 T
human embryonic kidney cells that were cultured in D-
MEM medium (Gibco/Invitrogen, Carlsbad, CA) with
10% fetal bovine serum (FBS) supplement (Gibco/
Invitrogen).
Pseudovirus infection assay
Pseudovirus infection assay was performed on Madin-
Darby Canine Kidney (MDCK) cells which were cultured
in D-MEM supplemented with 10% FBS. Overnight cul-
tured MDCK cells were incubated with pseudovirus in
the presence or absence of mAb for 1 or 4 hours at 37°C
before the pseudovirus mixture was removed by aspira-
tion. Pseudovirus treated MDCK cells were cultured 48
hours further before the infectivity was determined. The
infectivity of pseudovirus was determined by assaying the
transfected and expressed luciferase activity in those
MDCK cells. The MDCK cells were rinsed with PBS
before being solublized with 60 μLG l oL y s i sB u f f e ro f
Promega (Madison, WI) for 2 hours. Fifty μLo fc e l l
lysate was mixed with an equal volume of Bright-Glo
Luciferase Substrate in an opaque well/plate. The chemi-
luminescence was detected with a TopCount NXT of
Perkin Elmer (Waltham, MA).
Immunoblot and densitometry analysis
The immunostain blot was carried out with a 4-20% gradi-
ent SDS-polyacrylamide gel and transferred to a PVDF
membrane in a semidry blot transfer apparatus (BioRad).
Both the primary and the secondary antibodies were
diluted 1:5000 fold in PBS containing 2% non-fat milk.
The stains were developed with chemiluminescent sub-
strates of Invitrogen (Carlsbad, CA) and the band intensi-
ties were measured by a Typhoon scanner and analyzed by
ImageQuant TL of GE Healthcare (Piscataway, NJ).
Results and discussion
All 7 mAb were purified to near homogeneousity by pro-
tein A resin (Figure 1), but the yield of mAb from those 7
clones varied significantly (Table 2). Clone A, C, 3C4, and
6B8 are high yield but clone B, D, and 4H2 are low yield
(Table 2). The purified mAb was not diluted to uniform
concentrations, because we would like to observe the
virus neutralizing effect in the presence of highest mAb
concentration possible.
Since H5N1 avian influenza virus is highly pathogenic
and is not available for general laboratory use, we opted
for a pseudovirus that expresses H5 and N1 surface pro-
teins and contains a firefly luciferase reporter gene so that
its infectivity can be assessed by luciferase activity. A preli-
minary neutralization scan was summarized in Figure 2
left panel. Initial screen for antibody efficacy revealed that
most clones have slightly more effective suppression on
Vietnam 1194 pseudovirus than others, but the overall
suppressive effect is weak. Because the polybasic cleavage
Table 1 Peptide sequence alignment of antigen
constructs and hemagglutinin cleavage sites of Vietnam





Anhui 2005 RERRR K R↓GLFGAIAGFIEGG
↓ depicts protease cleavage site.
OVA: ovalbumin; KLH: keyhole limpet hemocyanin
Figure 1 Coomassie stain of protein A purified mAb after SDS-
PAGE separation. Lane M, size marker with molecular weight
labeled on the left (in KDa); Lane 1, mAb A, 25 μg; Lane 2, mAb B, 2
μg; Lane 3, mAb C, 25 μg; Lane 4, mAb D, 10 μg; Lane 5, mAb 3C4,
25 μg; Lane 6, mAb 4H2, 25 μg; Lane 7, mAb 6B8 25 μg. Sample
volumes were adjusted for their contents; mAb B and D can only
attain 2 and 10 μg even at maximum volume.
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viral surface, epitope accessibility on the hemagglutinin
may play a role in the neutralization assay [33]. Therefore,
pepsin digestion on mAb was employed to cleave off the
Fc domain and we examine if F (ab’)2 can result in a better
suppression during the pseudovirus infection assay. After
pepsin treatment (Figure 3), the efficacy of those 7 F(ab’)2
remained low and none of the clones provided more than
50% suppression on pseudovirus infection (Figure 2 right
panel).
All 7 monoclonal antibodies were subjected to epitope
peptide analysis by dot blot. The result showed that clone
A ,C ,3 C 4a n d6 B 8r e c o g n i z et h ef u l ll e n g t h1 8m e r i c
peptide only and are reactive to as little as 0.1 μgo ff u l l
length peptide (Figure 4, third row from the top). Other
three clones, B, D, 4H2 are not immunoreactive to any of
those peptides (up to 10 μg, data not shown). Since mAb
A, C, 3C4, and 6B8 are reactive to the full length epitopic
p e p t i d e( F i g u r e4 ) ,t h e yw e r ec h o s e nf o ram o r ed e t a i l e d
titration, as shown in Figure 5. All 4 mAb showed sup-
pressive effect when premixed with pseudovirus 1194 but
Table 2 Monoclonal antibody yield from protein A purification of mouse ascites
Clone Content
1 (μg/μL) Volume(mL) Yield
2 (mg) Deglycerol
3 (μg/μL)
A 14.5 2 18.0 10.9
B 1.1 0.2 0.2 0.1
C 18.0 1.7 30.0 17.4
D 3.3 0.2 0.7 0.5
3C4 56.0 1.1 59.0 31.8
4H2 9.9 0.4 3.8 5.7
6B8 50.0 0.6 27.9 28.3
1Monoclonal antibody contents in selected best fractions after protein A purification and Centricon enrichment before the addition of 50% glycerol. The
immunoglobulin content was determined by Bradford method with BSA as the standard.
2The yield was obtained by multiplying content (μg/μL) with the volume (mL).
3The mAb were stored at -;80°C freezer in the presence of 50% glycerol. The glycerol can interfere with the virus infection assay, so it is removed by another
round of protein A purification and the immunoglobulin content was determined again
Figure 2 Preliminary test of pseudovirus neutralization by mAb. Pseudovirus, Vietnam 1194, Turkey, Anhui, and VSV at 50x TCID50 were
premixed with 10 μL mAb for 1 hour at 37°C before infecting MDCK cells in a total volume of 100 μL. Due to disparity in Ab yield from the
ascites, protein contents in purified mAb vary significantly and antibody used in each assay is 109, 1, 174, 5, 318, 57, 283 μg for clone A, B, C, D,
3C4, 4H2, 6B8, respectively (left panel). The right panel is neutralization of pseudovirus infection by pepsin treated mAb. The amount of antibody
used in each assay is equivalent to 3.7 μL of mAb, which are 40.3, 0.4, 64.4, 1.9, 117.7, 21.1, 104.7 μg for clone A, B, C, D, 3C4, 4H2, 6B8,
respectively, see Method for detail. In both experiments, a control reference group that received no antibody was performed in parallel for each
pseudovirus and its observation was considered 100%.
Figure 3 Coomassie stain of pepsinized mAb after SDS-PAGE
separation. Lane M, size marker with molecular weight labeled on
the left (in KDa); Lane 1-7 are loaded with 20 μL of pepsin digestion
products as mentioned in Figure 2. Lane 1, mAb A, 16.1 μg; Lane 2,
mAb B, 0.1 μg; Lane 3, mAb C, 25.8 μg; Lane 4, mAb D, 0.7 μg; Lane
5, mAb 3C4, 47.1 μg; Lane 6, mAb 4H2, 8.4 μg; Lane 7, mAb 6B8
41.9 μg; Lane 8, pepsin 7.4 μg alone.
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(approximately 45%).
To verify if these purified mAb can bind to hemaggluti-
nin, mAb C, 3C4, and 6B8 were subjected to immunoblot-
ting against recombinant hemagglutinin or virus lysate, as
shown in Figure 6. The immunoblot indicated mAb C,
3C4, and 6B8 recognized the intact hemagglutinin (HA0)
but not its cleaved products, HA1 or HA2 (Figure 6,
right 3 panels) which is in agreement with the result of
epitopic peptide dot blotting (Figure 4). With the use of
polyclonal antibody against H5, analysis by densitometry
revealed that 3 quarters of hemagglutinin has already been
cut regardless whether it is viral origin or recombinant
hemagglutinin (Figure 6, left panel). When native H5
Figure 4 Epitope peptide analysis by dot blot. The full length 18 meric peptide is designated as Ag0, the N-half 8 meric peptide is
designated as Ag1 and the C-half 10 meric peptide is designated as Ag2. Monoclonal antibodies A, C, 6B8 and 3C4 are immunoreactive to the
full length peptide but not either half peptide. The immunoglobulin contents are 9.8, 40.0, 7.7 and 15.0 μg/μL for clone A, C, 6B8 and 3C4,
respectively, and were diluted 1:500 with 2% non-fat milk in PBS. Clone B, D, and 4H2 are not immunoreactive to any of these 3 peptides at up









































































































Figure 5 Suppression of MDCK cell infection by pseudovirus 1194 with mAb A (top left), C (top right), 3C4 (lower left), and 6B8 (lower
right). Y-axis indicates transfected firefly luciferase activity, expressed as fluorescence unit (FU). Pseudoviruses were premixed with mAb for 4
hours prior to infection on MDCK cells. All mAb showed substantial but weak suppression of infection by pseudovirus 1194. A concurrent series
of virus dilutions were performed in parallel in the absence of mAb as the control.
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cells were subject to mAb A, C, 3C4, 6B8 immunostaining,
the stain intensities on 293 cells were rather weak (data
not shown). The weak staining of native hemagglutinin is
in agreement with the fact that the majority of HA on the
influenza virus are cleaved before the virus is released
from its infected host.
Conclusions
Because our mAb cannot recognize those cleaved HA1 or
HA2 (Figures 4 and 6), the state of hemagglutinin cleavage
on the pseudovirus would explain why our mAb have lim-
ited influence on virus infection in Figures 2 and 5. The
small magnitude of suppression on pseudovirus infection
(no more than 50%) can be explained by the fact that the
majority of hemagglutinin on the pseudovirus is already
cut and too late for our mAb to exert any suppressive
effect. In order to reach the full potential of those mAb
that target HA cleavage site, one may need an inhibition
on those membrane bound proteases, like furin, propro-
tein convertase 5/6, or type II transmembrane serine pro-
teases, like TMPRSS2, 4, HAT [8,9], so that these mAb
can recognize its intact uncut epitope and prevent subse-
quent viral infection.
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